Evommune, a biopharmaceutical company focused on chronic inflammatory diseases, disclosed on Tuesday that it will discontinue development of its experimental eczema therapy, EVO756. The decision follows a mid‑stage (Phase II) trial that did not achieve the primary or secondary efficacy goals.
Trial results and immediate market reaction
The study enrolled 121 adult participants with moderate‑to‑severe atopic dermatitis, a chronic skin condition characterized by dry, red, itchy patches. Over a 12‑week treatment period, with follow‑up through week 14, investigators measured changes on a standardized eczema severity scale. According to Evommune, EVO756 did not produce a meaningful percent change on that scale, and none of the dose levels tested met the pre‑specified primary or secondary endpoints.
Following the announcement, Evommune’s shares fell roughly 24% in after‑hours trading, reflecting investor disappointment in the missed efficacy signal.
Company’s outlook and continued focus
Despite the setback in the eczema program, Evommune said it will continue to develop EVO756 for migraine prevention. “EVO756 was generally well tolerated with a safety profile consistent with prior studies, supporting its continued evaluation in migraine prophylaxis,” said Eugene Bauer, the company’s Chief Medical Officer.
Evommune also noted that its balance sheet is expected to fund operations through 2029, allowing the company to pursue its broader portfolio of programs aimed at addressing chronic inflammatory diseases.
Context for investors and patients
Mid‑stage trial failures are not uncommon in the biotech sector, where the path from early‑stage promise to market approval is fraught with scientific and regulatory hurdles. While the eczema indication will not move forward, the company’s decision to retain the migraine program reflects a strategic focus on therapeutic areas where the safety data remain encouraging.
Patients with atopic dermatitis and their families will need to look to other emerging treatments, including biologics and topical agents that have shown efficacy in recent years. The broader market continues to see robust investment in skin‑disease therapies, underscoring the high unmet need.
What’s next for Evommune?
Evommune’s leadership indicated that the company will allocate resources toward advancing the migraine indication, which could involve additional Phase II or Phase III studies depending on regulatory feedback and trial design. The firm’s financial outlook remains stable, with sufficient cash to sustain its pipeline activities for several years.
Stakeholders are encouraged to monitor upcoming corporate communications for updates on trial designs, enrollment timelines, and any potential partnerships that could accelerate development.
Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.
